Endo International PLC (NASDAQ:ENDP) has earned an average rating of “Hold” from the twenty-four ratings firms that are presently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $14.02.

Several analysts recently issued reports on the company. Stifel Nicolaus downgraded Endo International PLC from a “buy” rating to a “hold” rating and cut their price target for the stock from $22.00 to $15.00 in a report on Friday, June 9th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Endo International PLC in a research report on Thursday, June 8th. Canaccord Genuity set a $12.00 price target on Endo International PLC and gave the company a “hold” rating in a research report on Thursday, June 8th. ValuEngine cut Endo International PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Mizuho reiterated a “buy” rating and set a $19.00 price target (up from $18.00) on shares of Endo International PLC in a research report on Thursday, May 25th.

Shares of Endo International PLC (NASDAQ:ENDP) traded up 0.23% during trading on Friday, hitting $8.56. 4,321,183 shares of the stock were exchanged. The stock’s market cap is $1.91 billion. The firm has a 50 day moving average of $9.45 and a 200-day moving average of $11.07. Endo International PLC has a 52-week low of $7.41 and a 52-week high of $23.98.

Endo International PLC (NASDAQ:ENDP) last released its earnings results on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.19. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The company had revenue of $875.73 million for the quarter, compared to the consensus estimate of $832.66 million. During the same quarter last year, the business posted $0.86 EPS. Endo International PLC’s quarterly revenue was down 4.9% compared to the same quarter last year. Equities research analysts anticipate that Endo International PLC will post $3.51 earnings per share for the current fiscal year.

In other Endo International PLC news, CFO Blaise Coleman bought 6,500 shares of the stock in a transaction dated Tuesday, August 15th. The shares were bought at an average cost of $7.89 per share, with a total value of $51,285.00. Following the completion of the acquisition, the chief financial officer now owns 13,729 shares of the company’s stock, valued at $108,321.81. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Terrance J. Coughlin bought 20,000 shares of the stock in a transaction dated Thursday, August 10th. The shares were acquired at an average cost of $7.70 per share, for a total transaction of $154,000.00. Following the completion of the acquisition, the chief operating officer now directly owns 181,369 shares of the company’s stock, valued at approximately $1,396,541.30. The disclosure for this purchase can be found here. Insiders have acquired 36,000 shares of company stock valued at $279,460 over the last 90 days. Company insiders own 0.50% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in ENDP. OppenheimerFunds Inc. increased its stake in Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock valued at $32,065,000 after acquiring an additional 1,857,678 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after buying an additional 633,904 shares in the last quarter. Teachers Advisors LLC boosted its position in Endo International PLC by 1.9% in the second quarter. Teachers Advisors LLC now owns 840,470 shares of the company’s stock valued at $9,388,000 after buying an additional 15,928 shares in the last quarter. TIAA CREF Investment Management LLC boosted its position in Endo International PLC by 1.6% in the second quarter. TIAA CREF Investment Management LLC now owns 649,535 shares of the company’s stock valued at $7,255,000 after buying an additional 10,387 shares in the last quarter. Finally, Schneider Capital Management Corp boosted its position in Endo International PLC by 14.9% in the first quarter. Schneider Capital Management Corp now owns 642,311 shares of the company’s stock valued at $7,168,000 after buying an additional 83,100 shares in the last quarter. 90.74% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/07/endo-international-plc-endp-receives-14-02-average-price-target-from-brokerages.html.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International PLC (NASDAQ:ENDP)

Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.